Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves’ ophthalmopathy and hashimoto’s thyroiditis

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 1731-1740

  Lahooti, Hooshang ^a,b   Cultrone, Daniele ^a,b   Edirimanne, Senarath ^a,b   Walsh, John P ^c,d   Delbridge, Leigh ^a,e   Cregan, Patrick ^a,b   Champion, Bernard ^a,b   Wall, Jack R ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Nepean Executive Unit   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Autoimmune thyroiditis; Eye muscles antibodies; Genotyping; Heterozygous; Homozygous; Ophthalmology; Orbitopathy; Thyroid eye disease; Wild type

Indexed keywords

CALSEQUESTRIN; CALSEQUESTRIN 1; CALSEQUESTRIN 1 ANTIBODY; GENOMIC DNA; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CALSEQUESTRIN 1 GENE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC MARKER; GENOTYPE; HASHIMOTO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PREVALENCE; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 84942247255     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S87972     Document Type: Article

References (29)

1. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8): 726-738.
2. Abraham-Nordling M, Wallin G, Träisk F, et al; Thyroid Study Group of TT 96. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol. 2010;163:651-657.
3. Tjiang H, Lahooti H, McCorquodale T, Parmar KR, Wall JR. Eye and eyelid abnormalities are common in patients with Hashimoto’s thyroiditis. Thyroid. 2010;20:287-290.
4. Lahooti H, Parmar KR, Wall JR. Pathogenesis of Thyroid Eye Disease: important role of autoimmunity against calsequestrin and collagen XIII. Pathogenesis of Thyroid Eye Disease: important role of autoimmunity against calsequestrin and collagen XIII. A review. Clin Ophthalmol. 2010; 14:417-425.
5. Gopinath B, Tani J, Bao N, Wall JR. Eye muscle and collagen XIII antibodies and eye signs in patients with transient and chronic thyroiditis. Thyroid. 2007;17:1-7.
6. Khalilzadeh O, Noshad S, Rashidi A, Amirzargar A. Graves’ ophthalmopathy: a review of immunogenetics. Curr Genomics. 2011;12:564-575.
7. Liao WL, Wan L, Wang TY, et al. Association of TLR7 and TSHR copy number variation with Graves’ disease and Graves’ ophthalmopathy in Chinese population in Taiwan. BMC Ophthalmol. 2014;14:15.
8. Yamada M, Wu Li A, Wall J. Thyroid-associated ophthalmopathy: clini- cal features, pathogenesis, and management. Crit Rev Clin Lab Sci. 2000; 37(6):523-549.
9. Girgis CM, Champion BL, Wall JR. Current concepts in Graves’ disease. Ther Adv Endocrinol Metab. 2011;2(3):135-144.
10. McCorquodale T, Lahooti H, Gopinath B, Wall JR. Long-term follow-up of seven patients with ophthalmopathy not associated with thyroid autoimmunity: heterogeneity of autoimmune ophthalmopathy. Clin Ophthalmol. 2012;6:1063-1071.
11. Tani J, Gopinath B, Nuygen B, Wall JR. Immunological mechanisms for the eye muscle and orbital connective tissue reactions of thyroid-associated ophthalmopathy. Exp Rev Clin Immunol. 2007;3:299-311.
12. Gopinath B, Musselman R, Beard N, Tani J, Adams C, Wall JR. Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are sensitive and specific markers of ocular myopathy in patients with Graves’ disease. Clin Exp Immunol. 2006;145:56-62.
13. Nunery WR, Martin RT, Hinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthal Plast Reconstr Surg. 1993;9:77-82.
14. Gopinath B, Adams CL, Musselman R, Tani J, Wall JR. Antibodies against calsequestrin and type XIII collagen are good markers for chronic upper eyelid lag and retraction. Ocular Immunol Inflammation. 2007;15:81-88.
15. Wall JR, Lahooti H. Pathogenesis of thyroid eye disease - does autoimmu- nity against the TSH Receptor explain all cases? Endokrynol Pol. 2010;61(2):222-227.
16. Gopinath B, Musselman R, Adams C, Tani J, Beard N, Wall JR. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves’ disease with and without ophthalmopathy - correlation with clinical features. Thyroid. 2006;16:967-974.
17. Nguyen B, Gopinath B, Tani J, Wescombe L, Wall JR. Peripheral blood T lymphocyte sensitization against calsequestrin and flavoprotein in patients with Graves’ ophthalmopathy. Autoimmunity. 2008;41: 372-376.
18. Gopinath B, Wescombe L, Nguyen B, Wall JR. Can Autoimmunity against calsequestrin explain the eye and eyelid muscle inflammation of thyroid eye disease? Orbit. 2009;28:256-261.
19. Tani J, Wall JR. Analysis - Can the development of thyroid-associated ophthalmopathy be explained by autoimmunity against eye muscle antigens? Canad Med Assoc. 2006;17:239-241.
20. de Haan S, Lahooti H, Morris O, Wall JR. Epitopes, immunoglobulin classes and immunoglobulin G subclasses of calsequestrin antibodies in patients with thyroid eye disease. Autoimmunity. 2010;43(8): 698-703.
21. Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. PNAS. 2001;98:12062-12067.
22. Wescombe L, Lahooti H, Gopinath B, Wall JR. The cardiac calseques- trin gene (CASQ2) is up-regulated in the thyroid in patients with Graves’ ophthalmopathy - support for a role of autoimmunity against calseques- trin as the triggering event. Clin Endocrinol (Oxf). 2010;73:522-528.
23. Lahooti H, Cultrone D, Edirimanne S, et al. Association of the CASQ1 gene SNP rs3838216 with ophthalmopathy in patients with thyroid autoimmunity. Ophthalmol Res. 2014;2(6):281-293.
24. Walsh JP, Berry J, Liu S, et al. The clinical presentation of autoim- mune thyroid disease in men is associated with IL12B genotype. Clin Endocrinol (Oxf). 2011;74(4):508-512.
25. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Grave’s ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73: 639-644.
26. Werner SC. Classification of the eye changes of Graves’ disease. Am J Ophthalmol. 1969;68:646-648.
27. Cultrone D, Lahooti H, Edirimanne S, Delbridge L, Champion B, Wall JR. Calsequestrin is decreased in the thyroid gland of patients with Graves’ disease - further evidence for a role of autoimmunity against this protein in Graves’ ophthalmopathy. Br J Med Med Res. 2014;4(23): 4065-4075.
28. Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20(7):777-783.
29. Davies TF, Latif R, Yin X. New genetic insights from autoimmune thyroid disease. J Thyroid Res. 2012;2012:623852.